Blood Work Schedule

What this section covers

This page is the entry point for the blood work pages in this part of the site. It sums up which lab tests show up in clinical trials, on the labels of approved peptide medicines and in clinical guidelines, and it describes what users say they get tested. It isn't a testing plan. A clinician orders lab tests and interprets them, and the right panel depends on a person's health history and on the compound involved.

One point shapes everything below. Approved medicines such as tesamorelin and semaglutide come with FDA labels that say what to monitor. Peptides sold "for research use only" have no label at all, so there is no official monitoring schedule for them. What exists instead is a patchwork: trial protocols for related compounds, thresholds borrowed from general medicine, and community habits.

The three pages in this section

• Baseline testing before peptide use covers the labs people report getting before starting a compound, so later results have a reference point.
• On-cycle blood work monitoring covers the markers that trials and users track while a compound is in use, with most of the attention on IGF-1 and glucose.
• Post-cycle health assessment covers testing after stopping, including how long markers such as IGF-1 and HbA1c take to settle.

Each of those pages goes into more detail than this overview. The monitoring protocols overview looks at safety monitoring more broadly, including symptoms as well as lab values.

Why IGF-1 and glucose come up most

Growth hormone secretagogues are compounds that make the pituitary release more growth hormone. Growth hormone comes out in pulses, so a single growth hormone reading says little. IGF-1, the hormone the liver makes in response to growth hormone, moves much more slowly. That makes it the practical blood marker of growth hormone activity. Trials rely on it, and so do users.

Growth hormone also works against insulin. When it rises, blood sugar tends to rise with it. The longest controlled human data for an oral secretagogue comes from a 2-year randomized trial of MK-677 (ibutamoren) in 65 healthy adults aged 60 to 81, published in 2008. At 25 mg once daily, MK-677 raised growth hormone and IGF-1 to levels typical of healthy young adults. Fasting blood glucose rose by an average of 5 mg/dL (0.3 mmol/L), and insulin sensitivity fell. Lipids and cortisol were measured too, at baseline and every 6 months. Cortisol went up; LDL cholesterol dropped slightly.

An average rise of 5 mg/dL sounds small. It still explains why glucose stays on the panel: the shift runs in the direction that matters for anyone already close to the prediabetes range. The trial enrolled older adults, so it doesn't tell us how large the effect is in younger, leaner lifters.

What the tesamorelin label calls for

Tesamorelin is a growth-hormone-releasing hormone analogue. The FDA approved it as Egrifta to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, and the newer Egrifta WR formulation was approved in 2025. It's the closest thing to a labeled monitoring schedule for a growth-hormone-axis peptide.

As of October 2026, the Egrifta WR label's monitoring language centers on two markers. For IGF-1, it calls for monitoring during treatment and suggests prescribers consider stopping in patients whose levels stay high (for example, above 3 standard deviation scores), particularly when the fat-loss response is weak. In the trials, 47% of patients had IGF-1 above 2 standard deviation scores at 26 weeks and 36% were above 3, with the rise visible as early as week 13.

For glucose, the label calls for checking glucose status before treatment starts and periodically afterward, to catch impaired glucose tolerance or diabetes. By week 26 of the trials, 5% of tesamorelin patients reached an HbA1c of 6.5% or higher, against 1% on placebo. For patients who already have diabetes, the label also asks for regular checks for developing or worsening retinopathy, because IGF-1 goes up.

People using research-grade growth hormone peptides often borrow this logic when they describe their own testing. The label itself only covers the approved product in the population it was tested in.

GLP-1 medicines: fewer routine labs than many expect

As of October 2026, the labels for semaglutide (Wegovy) and tirzepatide (Zepbound) don't set a fixed blood-test calendar for every patient. Their monitoring language is targeted at specific situations:

• Kidney function in patients who report vomiting or other reactions that could cause dehydration, because acute kidney injury has been reported.
• Blood glucose before and during treatment in patients with diabetes (Wegovy), with a warning about low blood sugar when either drug is combined with insulin or an insulin secretagogue.
• Progression of diabetic retinopathy in patients with type 2 diabetes and a history of it (Zepbound, a warning updated in August 2026).

The Wegovy label also asks for heart rate checks at regular intervals.

Two lab findings from these labels come up often in community threads. Both drugs raised the pancreatic enzymes amylase and lipase in trials, with average lipase increases of roughly 28% to 39%, and both labels say the clinical meaning is unknown without other signs of pancreatitis. The labels also state that routine calcitonin testing or thyroid ultrasound is of uncertain value for catching medullary thyroid cancer and may lead to unnecessary procedures.

Standard panels and glucose cut-offs

Outside the compound-specific markers, the panels that come up most in clinic guides and forum posts are general ones: a complete blood count (CBC), a comprehensive metabolic panel (CMP, which includes glucose along with kidney and liver markers) and a lipid panel. None of these is peptide-specific. They're routine tests a clinician uses to spot an existing problem or a change from a person's earlier results.

For glucose results, the American Diabetes Association's ranges are the usual reference:

The ADA notes that a diabetes diagnosis usually needs a repeat test on a second day. HbA1c reflects average glucose over the past two to three months, so a retest a few weeks after a change won't show its full effect.

What users report getting tested

In community threads and clinic blog posts, the panel described for growth hormone peptides usually centers on IGF-1, fasting glucose and HbA1c, often with fasting insulin added, on top of the standard panels above. Posts about GLP-1 compounds lean toward HbA1c and kidney markers, and some add lipase. For BPC-157 and TB-500, many users say they skip routine labs or check only liver enzymes; we found no trial that defines what to measure for either compound.

Timing varies more than the panels do. Some posts describe a first recheck at 6 to 8 weeks, others at 8 to 12 weeks, and others only before and after a cycle. None of these intervals has been tested in a study. They're community conventions, sometimes adapted from the tesamorelin label or from general diabetes screening.

Users also raise practical sources of noise. A common suggestion in these threads is to use the same lab for every draw because assays and reference ranges differ. Keeping fasting conditions the same comes up just as often. Another point comes up with research-use products specifically: a lab result can't show what was in the vial. An IGF-1 level that doesn't move may reflect the product as much as the person.

Where lab results fit with other safety checks

Blood tests are one part of monitoring. Symptoms such as swelling or numbness can appear before any lab value changes, and the warning signs page covers what users and labels describe. Some existing conditions change the risk picture before any blood is drawn; those are covered under contraindicated conditions.

What we still don't know

No trial has tested a monitoring schedule for any unapproved research peptide, so the intervals passed around online are habits, not evidence. The long-term effect of holding IGF-1 above the normal range is also unknown; the tesamorelin label says so directly. And most of the glucose data comes from older adults or people with HIV lipodystrophy, not the healthy lifters who make up much of the community using these compounds.